Over-expression of Wild-type p53-induced phosphatase 1 confers poor prognosis of patients with gliomas

Brain Research

Volumn 1444, Issue , 2012, Pages 65-75

  Liang, Chaohui ^a   Guo, Erkun ^a   Lu, Shengkui ^a   Wang, Shuai ^a   Kang, Chunsheng ^b   Chang, Liang ^a   Liu, Liqiang ^a   Zhang, Guangyu ^a   Wu, Zhendong ^a   Zhao, Zongmao ^a   Ma, Shucheng ^a   Wang, Liqun ^a   Jiao, Bao Hua ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

^b Tian Jin Normal University   (China)

Author keywords

Glioma; Prognosis; Proliferating cell nuclear antigen; Wild type p53 induced phosphatase 1

Indexed keywords

CYCLINE; MESSENGER RNA; PHOSPHOPROTEIN PHOSPHATASE 2; PROTEIN P53; UNCLASSIFIED DRUG; WILD TYPE P53 INDUCED PHOSPHATASE 1;

ADOLESCENT; ADULT; AGED; ARTICLE; ASTROCYTOMA; BRAIN TISSUE; CANCER PROGNOSIS; CHILD; CLINICAL EVALUATION; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OLIGODENDROGLIOMA; OVERALL SURVIVAL; POSTOPERATIVE PERIOD; PRESCHOOL CHILD; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHOOL CHILD; UNIVARIATE ANALYSIS; WESTERN BLOTTING;

ADOLESCENT; ADULT; AGED; ANALYSIS OF VARIANCE; BRAIN; BRAIN NEOPLASMS; CHILD; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA; HUMANS; MALE; MIDDLE AGED; PHOSPHOPROTEIN PHOSPHATASES; PROLIFERATING CELL NUCLEAR ANTIGEN; STATISTICS, NONPARAMETRIC; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P53; YOUNG ADULT;

EID: 84862786611     PISSN: 00068993     EISSN: 18726240     Source Type: Journal    
DOI: 10.1016/j.brainres.2011.12.052     Document Type: Article

References (31)

1. J. Bartkova, Z. Horejsí, K. Koed, A. Krämer, F. Tort, K. Zieger, P. Guldberg, M. Sehested, J.M. Nesland, C. Lukas, T. ∅rntoft, J. Lukas, and J. Bartek DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis Nature 434 2005 864 870 (Pubitemid 40558993)
2. E.W. Baxter, and J. Milner p53 regulates LIF expression in human medulloblastoma cells J. Neurooncol. 97 2010 373 382
3. D.V. Bulavin, O.N. Demidov, S. Saito, P. Kauraniemi, C. Phillips, S.A. Amundson, C. Ambrosino, G. Sauter, A.R. Nebreda, C.W. Anderson, A. Kallioniemi, A.J. Fornace Jr., and E. Appella Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity Nat. Genet. 31 2002 210 215
4. D.V. Bulavin, C. Phillips, B. Nannenga, O. Timofeev, L.A. Donehower, C.W. Anderson, E. Appella, and A.J. Fornace Jr. Inactivation of the Wip1 phosphatase inhibits mammary tumorigenesis through p38 MAPK-mediated activation of the p16 (Ink4a)-p19 (Arf) pathway Nat. Genet. 36 2004 343 350 (Pubitemid 38437256)
5. R.C. Castellino, M. De Bortoli, X. Lu, S.H. Moon, T.A. Nguyen, M.A. Shepard, P.H. Rao, L.A. Donehower, and J.Y. Kim Medulloblastomas overexpress the p53-inactivating oncogene WIP1/PPM1D J. Neuro-oncology 86 2008 245 256
6. H. Cha, J.M. Lowe, H. Li, J.S. Lee, G.I. Belova, D.V. Bulavin, and A.J. Fornace Jr. Wip1 directly dephosphorylates gamma-H2AX and attenuates the DNA damage response Cancer Res. 70 2010 4112 4122
7. Mee-Yon Cho, Soon-hee Jung, and Tai Seung Kim p53 protein overexpression in astrocytic neoplasms Yonsei Med. J. 36 1995 521 526
8. A.R. Dehdashti, M.E. Hegi, L. Regli, A. Pica, and R. Stupp New trends in the medical management of glioblastoma multiforme: the role of temozolomide chemotherapy Neurosurg. Focus. 20 2006 E6
9. O.N. Demidov, C. Kek, S. Shreeram, O. Timofeev, A.J. Fornace, E. Appella, and D.V. Bulavin The role of the MKK6p38 MAPK pathway in Wip1-dependent regulation of ErbB2-driven mammary gland tumorigenesis Oncogene 26 2007 2502 2506 (Pubitemid 46597262)
10. Mary F. Dempsey, Barrie R. Condon, and Donald M. Hadley Measurement of tumor "size" in recurrent malignant glioma: 1D, 2D, or 3D? Am. J. Neuroradiol. 26 2005 770 776 (Pubitemid 43079766)
11. M. Fiscella, H. Zhang, S. Fan, K. Sakaguchi, S. Shen, Edward M. Mercer, G.F. Vande Woude, P.M. O'Connor, and E. Appella Wip1, a novel human protein phosphatase that is induced in response to ionizing radiation in a p53-dependent manner Proc. Natl. Acad. Sci. U. S. A. 94 1997 6048 6053 (Pubitemid 27270633)
12. V.G. Gorgoulis, L.V. Vassiliou, P. Karakaidos, P. Zacharatos, A. Kotsinas, T. Liloglou, M. Venere, R.A.J. Ditullio, N.G. Kastrinakis, B. Levy, D. Kletsas, A. Yoneta, M. Herlyn, C. Kittas, and T.D. Halazonetis Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions Nature 434 2005 907 913 (Pubitemid 40559004)
13. A. Hirasawa, F. Saito-Ohara, J. Inoue, D. Aoki, N. Susumu, T. Yokoyama, S. Nozawa, J. Inazawa, and I. Imoto Association of 17q21-q24 gain in ovarian clear cell adenocarcinomas with poor prognosis and identification of PPM1D and APPBP2 as likely amplification targets Clin. Cancer Res. 9 2003 1995 2004 (Pubitemid 36687618)
14. W. Hu, Zh. Feng, I. Modica, D.S. Klimstra, L. Song, P.J. Allen, M.F. Brennan, A.J. Levine, and L.H. Tang Gene amplifications in well-differentiated pancreatic neuroendocrine tumors inactivate the p53 pathway Genes Cancer 1 2010 360 368
15. Yasuo Iwadate, Junetsu Mizoe, Yasuhiro Osaka, Akira Yamaura, and Hirohiko Tsujii High Linear EnergyTransfer Carbon Radiation Effectively Kills Cultured Glioma Cells with Either Mutant or Wild-type p53 Int. J. Radiat. Oncol. Biol. Phys. 50 2001 803 808 (Pubitemid 32515335)
16. P. Kleihues, D.N. Louis, B.W. Scheithauer, L.B. Rorke, G. Reifenberger, P.C. Burger, and W.K. Cavenee The WHO classification of tumours of the nervous system J. Neuropathol. Exp. Neurol. 61 2002 215 225 (Pubitemid 34212595)
17. P. Kleihues, P.C. Burger, K.D. Aldape, D.J. Brat, W. Biernat, D.D. Bigner, Y. Nakazato, K.H. Plate, F. Giangespero, A. von Deimling, H. Ohgaki, and W.K. Cavenee D.N. Louis, H. Ohgaki, O.D. Wiestler, W.K. Cavanee, WHO Classification of Tumors of the Central Nervous System 2007 IARC Press Lyon 33 49
18. M. Klein, J.M. Vignaud, V. Hennequin, B. Toussaint, L. Bresler, F. Plénat, J. Leclère, A. Duprez, and G. Weryha Increased expression of the vascular endothelial growth factor is a pejorative prognosis marker in papillary thyroid carcinoma J. Clin. Endocrinol. Metab. 86 2001 656 658 (Pubitemid 32207476)
19. J. Li, Y. Yang, Y. Peng, R.J. Austin, W.G. Van Eyndhoven, K.C. Nguyen, T. Gabriele, M.E. McCurrach, J.R. Marks, T. Hoey, S.W. Lowe, and S. Powers Oncogenic properties of PPM1D located within a breast cancer amplification epicenter at 17q23 Nat. Genet. 31 2002 133 134
20. Wei Li, Dake Chu, Xiaodan Chu, Fanhua Meng, Dun Wei, Haiping Li, and Boqian Sun Decreased expression of NDRG2 is related to poor overall survival in patients with glioma J. Clin. Neurosci. 18 2011 1534 1537
21. D.N. Louis, H. Ohgaki, O.D. Wiestler, W.K. Cavenee, P.C. Burger, A. Jouvet, B.W. Scheithauer, and P. Kleihues The 2007 WHO classification of tumours of the central nervous system Acta Neuropathol. 114 2007 97 109 (Pubitemid 47103521)
22. X. Lu, T.A. Nguyen, S.H. Moon, Y. Darlington, M. Sommer, and A. Lawrence The type 2C phosphatase Wip1: an oncogenic regulator of tumor suppressor and DNA damage response pathways Cancer Metastasis Rev. 27 2008 123 135
23. Leandro Luongo de Matos, Elaine Stabenow, Marcos Roberto Tavares, Alberto Rosseti Ferraz, Vera Luiza Capelozzi, and Maria Aparecida da Silva Pinhal Immunohistochemistry quantification by a digital computer-assisted method compared to semiquantitative analysis Clinics 61 2006 417 424 (Pubitemid 44639401)
24. B. Nannenga, X. Lu, M. Dumble, M. Van Maanen, T.A. Nguyen, R. Sutton, T.R. Kumar, and L.A. Donehower Augmented cancer resistance and DNA damage response phenotypes in PPM1D null mice Mol. Carcinog. 45 2006 594 604 (Pubitemid 44205099)
25. M. Rossi, O.N. Demidov, C.W. Anderson, E. Appella, and S.J. Mazur Induction of PPM1D following DNA-damaging treatments through a conserved p53 response element coincides with a shift in the use of transcription initiation sites Nucleic Acids Res. 36 2008 7168 7180
26. F. Saito-Ohara, I. Imoto, J. Inoue, H. Hosoi, A. Nakagawara, T. Sugimoto, and J. Inazawa PPM1D is a potential target for 17q gain in neuroblastoma Cancer Res. 63 2003 1876 1883 (Pubitemid 36460852)
27. N. Satoh, Y. Maniwa, V.P. Bermudez, K. Nishimura, W. Nishio, M. Yoshimura, Y. Okita, C. Ohbayashi, J. Hurwitz, and Y. Hayashi Oncogenic phosphatase Wip1 is a novel prognostic marker for lung adenocarcinoma patient survival Cancer Sci. 102 2011 1101 1106
28. J.A. Schwartzbaum, J.L. Fisher, K.D. Aldape, and M. Wrensch Epidemiology and molecular pathology of glioma Nat. Clin. Pract. Neurol. 2 2006 494 503 (Pubitemid 44275725)
29. J.Y. Song, H.S. Han, K. Sabapathy, B.M. Lee, E. Yu, and J. Choi Expression of a homeostatic regulator, Wip1 (wild-type p53-induced phosphatase), is temporally induced by c-Jun and p53 in response to UV irradiation J. Biol. Chem. 285 2010 9067 9076
30. B. Vojtesek, J. Bartek, C.A. Midgley, and D.P. Lane An immunochemical analysis of the human nuclear phosphoprotein p53: new monoclonal antibodies and epitope mapping using recombinant p53 J. Immunol. Methods 151 1992 237 244
31. E. Yu, Y.S. Ahn, S.J. Jang, M.J. Kim, H.S. Yoon, G. Gong, and J. Choi Overexpression of the wip1 gene abrogates the p38 MAPK/p53/Wip1 pathway and silences p16 expression in human breast cancers Breast Cancer Res. Treat. 101 2007 269 278 (Pubitemid 46169880)